Outcome Survey Of Specific Use Of 12.5 Mg Sutent Capsule Against Gastrointestinal Stromal Tumor: Implementation Guidelines.
Phase of Trial: Phase IV
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 20 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2015 Planned End Date changed from 1 Oct 2014 to 1 Jul 2016 as reported by ClinicalTrials.gov.